Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
NCT01205581
Completed
This is an open label-study of Fluzone HD, a high-dose form of trivalent, inactivated influenza vaccine (TIV), vs. Fluzone, a standard-dose form of TIV. Subjects with cancer or HIV will be vaccinated twice with one of the two vaccines and evaluated for development of immune responses.
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
09/20/2016
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: HIV, Cancer
Register for Updates
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT02237209
Completed
Respiratory syncytial virus (RSV) is a common cause of illness in infants and children around the world. This study will evaluate the safety and immune response to an RSV vaccine in RSV-seronegative infants and children. This study is a companion study to CIR 291.
Gender:
ALL
Ages:
Between 6 months and 24 months
Trial Updated:
10/07/2015
Locations: St. Jude Children's Research Hospital CRS, Memphis, Tennessee
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
NCT00006470
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with radiation therapy in treating patients who have stage II or stage IIIA non-small cell lung cancer that has been completely removed in surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2013
Locations: Jackson-Madison County General Hospital, Jackson, Tennessee +2 locations
Conditions: Lung Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT00003386
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: CCOP - Baptist Cancer Institute, Memphis, Tennessee +1 locations
Conditions: Ovarian Cancer
Register for Updates
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
NCT00002748
Completed
RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or recurrent neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
10/03/2011
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
NCT00094653
Completed
The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an obje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2011
Locations: Family Cancer Center, Bartlett, Tennessee +4 locations
Conditions: Melanoma, Metastases
Register for Updates